Search Within

GDMT, Medicine

Formats
  1. Journal Article (916)
  2. Meeting Abstract (825)
  3. Review (46)
  4. Book Section (38)
  5. Editorial (28)
  6. Guidelines (18)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1879)
  2. Department of Medicine (1870)
  3. Solid Tumor Oncology Division (1868)
  4. Gynecologic Medicine Service (1828)
  5. Surgery (576)
  6. GDMT, Surgery (462)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (277)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (42)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Gynecologic Oncology (416)
  2. Journal of Clinical Oncology (414)
  3. International Journal of Gynecological Cancer (148)
  4. Annals of Oncology (106)
  5. Clinical Cancer Research (61)
  6. Cancer (37)

More Publications

Publishers
  1. Elsevier Inc. (494)
  2. American Society of Clinical Oncology (445)
  3. Lippincott Williams & Wilkins (173)
  4. American Association for Cancer Research (136)
  5. Oxford University Press (128)
  6. Nature Publishing Group (71)

More Publishers

Results (1879)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)
    Meeting Abstract

    Erickson, B. K.; Enserro, D.; Lankes, H. A.; Dockery, L. E.; Ghamande, S. A.; Oliver, M. T.; Gressel, G. M.; Castellano, T.; Ratner, E.; Deery, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study
    Meeting Abstract

    Rojas, C.; Eskens, F.; Ghiringhelli, F.; Özgüroglu, M.; Caglevic, C.; Gumus, M.; Tosi, D.; Grenier, J.; Gonzalez, A. F.; Arenas, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis
    Meeting Abstract

    Makker, V.; Richardson, D. L.; Chon, H. S.; Miller, D. S.; Mau-Sorensen, M.; Cibula, D.; Zagouri, F.; Fidalgo, A. P.; Slomovitz, B. M.; Coleman, R. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)
    Meeting Abstract

    Lee, J. Y.; Ryoo, B. Y.; Kim, J. W.; Cheng, A. L.; Finn, R. S.; Hasegawa, K.; Makker, V.; Kudo, M.; Miller, D. S.; Merle, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 safety and efficacy of IMC-F106C, a PRAME x CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
    Meeting Abstract

    Hamid, O.; Williams, A.; Lopez, J. S.; Olson, D.; Sato, T.; Shaw, H. M.; Friedman, C. F.; Thistlethwaite, F.; Middleton, M. R.; Lebbe, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Wysocki, P. J.; Jung, K. H.; Oh, D. Y.; Doroshow, D. B.; Artamonova, E.; Mammatas, L.; Su, P. J.; Moiseyenko, V.; Penkov, K.; Stroyakovskiy, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023
    Meeting Abstract

    Dignam, J. J.; Romitti, P. A.; Yom, S. S.; Feng, F. Y.; Bradley, J. D.; Mehta, M. P.; Bruner, D. W.; Wenzel, J.; Mamounas, E. P.; George, T. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer
    Meeting Abstract

    Gaillard, S.; Starodub, A.; O'Neil, B.; Mathews, C. A.; Dumbrava, E. E.; Friedman, C. F.; Swiecicki, P.; Oh, C.; Andreu, C.; Lee, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
    Meeting Abstract

    Dockery, L. E.; Slomovitz, B. M.; Musa, F.; Mathews, C. A.; Priebe, A. M.; Green, A.; Puechl, A.; Birrer, M. J.; Spirtos, N. M.; Ding, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save